Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation :
a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals. In the context of the current opioid crisis, we aim to become the key player of reference in the pain field, through the design and proposition of new active pharmaceutical ingredients based on the development of first-in-class polypeptides derived from TAFA4.
Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein that modulates the transmission of pain information to the brain.
Tafalgie Therapeutics has developed and identified other new drug candidates.
Tafalgie Therapeutics has formed a scientific committee and a supervisory board to assist its management team and the founding partners.
Become the leader in the field of analgesia with a full range of solutions in a market expected to reach $100bn by 2030.
Provide patients with high-efficacy, high-tolerability, and non-addictive drugs for acute severe pain, as well as for prevention and treatment of chronic refractory pain, in a context marked by the opioid crisis.
surgical interventions are performed annually
undergoing surgery experience pain
people in Europe suffer from chronic pain.
do not receive appropriate treatment for their pain.
“ Pain is considered to be the root cause of almost two thirds of medical consultations. For this reason, it is the subject of many studies, both fundamental and clinical.
Active research on this subject IS absolutely essential to improve our understanding of the mechanisms involved in pain and for the development of new treatments. ”
Aziz Moqrich explains to Thierry Lhermitte (France Inter) how pain is modulated in the human body.